(Q24235484)

25 October 2023

Jing Zhang

1

Jing

Zhang

1 reference

25 October 2023

Tingting Li

2

Tingting

Li

1 reference

25 October 2023

Lingling Zhou

3

Lingling

Zhou

1 reference

25 October 2023

Liulin Tang

4

Liulin

Tang

1 reference

25 October 2023

Liangzhi Xu

5

Liangzhi

Xu

1 reference

25 October 2023

Danforn CE Lim

7

Danforn Ce

Lim

1 reference

Cochrane Database of Systematic Reviews

25 October 2023

language of work or name

1 reference

8 September 2010

0 references

published in

0 references

cites work

Effects of Chinese green tea on weight, and hormonal and biochemical profiles in obese patients with polycystic ovary syndrome--a randomized placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007535.PUB2

Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007535.PUB2

A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007535.PUB2

Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007535.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007535.PUB2

Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007535.PUB2

The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007535.PUB2

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007535.PUB2

Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007535.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007535.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007535.PUB2

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007535.PUB2

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007535.PUB2

Chinese herbal nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007535.PUB2

Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007535.PUB2

Increased prevalence of gestational diabetes mellitus among women with diagnosed polycystic ovary syndrome: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007535.PUB2

Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007535.PUB2

Urothelial malignant disease and Chinese herbal nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007535.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007535.PUB2

Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007535.PUB2

Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007535.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007535.PUB2

Long versus short course treatment with Metformin and Clomiphene Citrate for ovulation induction in women with PCOS

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007535.PUB2

Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007535.PUB2

Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007535.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Effects of switching to wen-jing-tang (unkei-to) from preceding herbal preparations selected by eight-principle pattern identification on endocrinological status and ovulatory induction in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007535.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/14651858.CD007535.PUB2

0 references

Fatcat ID

release_ryqee7kqz5davmnza3anlxsi4i

0 references